Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2018-04-12
- Target Recruit Count
- 16
- Registration Number
- NCT00037102
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
- Conditions
- Locations
- 🇺🇸
MidAmerica Neuroscience Institute, Kansas City, Missouri, United States
Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 210
- Registration Number
- NCT00036153
- Locations
- 🇺🇸
Arthritis & Rheumatology Associates of Palm Beach, West Palm Beach, Florida, United States
🇺🇸Radiant Research - Dallas, Dallas, Texas, United States
🇺🇸Rheumatology Associates of North Alabama, Huntsville, Alabama, United States
Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 75
- Registration Number
- NCT00035958
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00035074
- Locations
- 🇺🇸
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Phase I Study of Methotrexate for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 30
- Registration Number
- NCT00000834
- Locations
- 🇺🇸
Cedars Sinai Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Kansas School of Medicine, Wichita, Kansas, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 45
- Registration Number
- NCT00000723
- Locations
- 🇺🇸
Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 250
- Registration Number
- NCT00000658
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 45
- Registration Number
- NCT00000703
- Locations
- 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000689
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.